Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 663-670

  Smid, Scott D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bimatoprost; Endocannabinoid; Glaucoma; Prostamides; Trabecular meshwork

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; BIMATOPROST; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRONABINOL; ENDOCANNABINOID; LATANOPROST; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN ETHANOLAMIDE DERIVATIVE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; REVIEW; TRABECULAR MESHWORK;

EID: 77953446378     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s6337     Document Type: Review

References (70)

1. Mackenzie P, Cioffi G. How does lowering of intraocular pressure protect the optic nerve? Surv Ophthalmol. 2008;53(Suppl 1):S39-S43.
2. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 2009;88:713-717.
3. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res. 1999;18:91-119.
4. Liton PB, Luna C, Challa P, Epstein DL, Gonzalez P. Genome-wide expression profile of human trabecular meshwork cultured cells, non-glaucomatous and primary open angle glaucoma tissue. Mol Vis. 2006;12:774-790.
5. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res. 2005;81:1-4.
6. Overby DR, Stamer WD, Johnson M. The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res. 2009;88:656-670.
7. Johnson DH. Trabecular meshwork and uveoscleral outflow models. J Glaucoma. 2005;14:308-310.
8. Woodward DF, Gil DW. The inflow and outflow of anti-glaucoma drugs. Trends Pharmacol Sci. 2004;25:238-241.
9. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57-S68.
10. Sharts-Hopko NC, Glynn-Milley C. Primary open-angle glaucoma. Am J Nurs. 2009;109:40-47; quiz 48.
11. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112-115.
12. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19:231-248.
13. Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92:7-12.
14. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(Suppl 1):S69-S84.
15. Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008;30:622-632.
16. van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279-1283.
17. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(Suppl 1):S107-S120.
18. Stumpff F, Wiederholt M. Regulation of trabecular meshwork contractility. Ophthalmologica. 2000;214:33-53.
19. Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 2006;19:151-158.
20. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271-295.
21. Wiederholt M. Direct involvement of trabecular meshwork in the regulation of aqueous humor outflow. Curr Opin Ophthalmol. 1998;9:46-49.
22. Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007;48:4107-4115.
23. Thieme H, Steinhausen K, Ottlecz A, et al. Effects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cells. Ophthalmic Res. 2005;37:293-300.
24. Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009;50:5259-5265.
25. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin- ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153:410-419.
26. Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol. 2005;1:151-157.
27. Wan Z, Woodward DF, Stamer WD. Endogenous bioactive lipids and the regulation of conventional outflow facility. Expert Rev Ophthalmol. 2008;3:457-470.
28. Russ HH, Costa VP, Ferreira FM, et al. Conjunctival changes induced by prostaglandin analogues and timolol maleate: a histomorphometric study. Arq Bras Oftalmol. 2007;70:910-916.
29. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419-4426.
30. How AC, Kumar RS, Chen YM, et al. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol. 2009;93:782-786.
31. Kurtz S, Mann O. Incidence of hyperemia associated with bimatoprost treatment in naive subjects and in subjects previously treated with latanoprost. Eur J Ophthalmol. 2009;19:400-403.
32. Kammer J, Katzman B, Ackerman S, Hollander D. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomized, masked-evaluator, multicenter study. Br J Ophthalmol. 2009 Sep 1. [Epub ahead of print].
33. Chen J, Dinh T, Woodward DF, et al. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23:231-246.
34. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621.
35. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450.
36. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93-S105.
37. Rodrigues Mde L, Felipe Crosta DP, Soares CP, et al. Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment. J Glaucoma. 2009;18:197-200.
38. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877-44885.
39. Weber A, Ni J, Ling KH, et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res. 2004;45:757-763.
40. Moriuchi H, Koda N, Okuda-Ashitaka E, et al. Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily. J Biol Chem. 2008;283:792-801.
41. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev. 2005;48:352-359.
42. Woodward DF, Carling RW, Cornell CL, et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther. 2008;120:71-80.
43. Burk RM, Woodward DF. A historical perspective and recent advances in prostamide research and therapeutics. Curr Opin Drug Discov Devel. 2007;10:413-421.
44. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337-S345.
45. Smid SD. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine. Clin Exp Pharmacol Physiol. 2008;35(11):1383-1387.
46. Chen J, Lu RT, Lai R, et al. Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009;34:184-195.
47. Matias I, Chen J, De Petrocellis L, et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther. 2004;309:745-757.
48. Woodward DF, Krauss AH, Wang JW, et al. Identif ication of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris. Br J Pharmacol. 2007;150:342-352.
49. Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19:45-54.
50. Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci. 2007;48:3677-3682.
51. Szczesniak AM, Kelly ME, Whynot S, Shek PN, Hung O. Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats. J Ocul Pharmacol Ther. 2006;22:160-167.
52. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, Kelly ME. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol. 2007;152:1111-1120.
53. Liang Y, Woodward DF, Guzman VM, et al. Identif ication and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079-1093.
54. Wei Y, Wang X, Wang L. Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells. Mol Vis. 2009;15:1243-1251.
55. Stamer WD, Golightly SF, Hosohata Y, et al. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol. 2001;431:277-286.
56. Crandall J, Matragoon S, Khalifa YM, et al. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res. 2007;39:69-75.
57. Njie YF, He F, Qiao Z, Song ZH. Aqueous humor outflow effects of 2-arachidonylglycerol. Exp Eye Res. 2008;87:106-114.
58. Njie YF, Qiao Z, Xiao Z, Wang W, Song ZH. N-arachidonylethanolamide- induced increase in aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2008;49:4528-4534.
59. Chen J, Matias I, Dinh T, et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330:1062-1067.
60. Maihofner C, Schlotzer-Schrehardt U, Guhring H, et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci. 2001;42:2616-2624.
61. Rosch S, Ramer R, Brune K, Hinz B. R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther. 2006;316:1219-1228.
62. Rosch S, Ramer R, Brune K, Hinz B. Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases. Biochem Biophys Res Commun. 2005;338:1171-1178.
63. Nucci C, Gasperi V, Tartaglione R, et al. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci. 2007;48:2997-3004.
64. Marshall JL, Stanfield KM, Silverman L, Khan KN. Enhanced expression of cyclooxygenase-2 in glaucomatous dog eyes. Vet Ophthalmol. 2004;7:59-62.
65. Glass M, Hong J, Sato TA, Mitchell MD. Misidentif ication of prostamides as prostaglandins. J Lipid Res. 2005;46:1364-1368.
66. Hinz B, Rosch S, Ramer R, Tamm ER, Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 2005;19:1929-1931.
67. Fraunfelder FW, Solomon J, Mehelas TJ. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol. 2006;124:277-279.
68. Radi ZA, Render JA. The pathophysiologic role of cyclo-oxygenases in the eye. J Ocul Pharmacol Ther. 2008;24:141-151.
69. Costagliola C, Parmeggiani F, Caccavale A, Sebastiani A. Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma. Am J Ophthalmol. 2006;141:379-381.
70. Nucci C, Bari M, Spano A, et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 2008;173:451-464.